Novozymes and ProMetic Life Sciences have entered into a strategic alliance regarding proprietary albumin purification technology that is based upon a synthetic-ligand affinity adsorbent developed by the latter's UK subsidiary, ProMetic BioSciences.
The purification technology has been designed for the rapid and cost-effective development of the former's albufuse albumin-fusion molecules.
Under the terms of the co-marketing alliance the companies will jointly promote the use of a new synthetic-ligand affinity adsorbent, marketed under the trade-name AlbuPure, as a platform approach for the purification of albumin and albumin-fusion proteins.
ProMetic will be the exclusive manufacturer and supplier of AlbuPure, however both parties will retain ownership of their respective technologies and both companies will have the right to market AlbuPure.
Share this: 
Del.icio.us |
Email This | 
Printer Friendly
